Scarlet Fever

1. Clinical Overview

Summary

Scarlet Fever (Scarlatina) is an acute exotoxin-mediated infectious disease caused by Group A β-haemolytic Streptococcus (GAS), specifically Streptococcus pyogenes strains that produce Streptococcal Pyrogenic Exotoxins (SPEs). It predominantly affects children aged 2-10 years and is characterised by the classic triad of fever, pharyngitis/tonsillitis, and a distinctive fine, punctate, erythematous "sandpaper" rash. [1,2]

The condition manifests with pathognomonic clinical features including Strawberry Tongue (initially white-coated with erythematous papillae, later denuded and beefy-red), flushed cheeks with circumoral pallor, Pastia's Lines (linear petechiae in flexural areas), and subsequent desquamation during convalescence. The rash represents a hypersensitivity reaction to erythrogenic exotoxins in non-immune individuals. [3,4]

Scarlet Fever is a Notifiable Disease in the United Kingdom under the Health Protection (Notification) Regulations 2010. The UK has experienced a significant resurgence since 2014, with record case numbers reported in 2022-2023, alongside increased invasive Group A Streptococcus (iGAS) disease. [5,6]

First-line treatment is Phenoxymethylpenicillin (Penicillin V) administered for 10 days to eradicate the organism, prevent post-streptococcal complications (particularly Acute Rheumatic Fever), reduce transmission, and shorten symptom duration. Alternative antibiotics include azithromycin or clarithromycin for penicillin-allergic patients. [7,8]

While most cases are uncomplicated and self-limiting, potential complications include suppurative (peritonsillar abscess, otitis media, sinusitis, cervical lymphadenitis) and non-suppurative sequelae (Acute Rheumatic Fever, Post-Streptococcal Glomerulonephritis), as well as invasive disease (bacteraemia, necrotising fasciitis, Streptococcal Toxic Shock Syndrome). [9,10]

Clinical Pearls

"The Sandpaper Rash": The pathognomonic rash has a rough, fine, punctate texture resembling fine-grade sandpaper. It blanches on pressure and becomes more pronounced in skin creases, creating Pastia's Lines.

"Strawberry Tongue Progression": Day 1-2: White Strawberry Tongue (white coating with protruding red papillae). Day 4-5: Red Strawberry Tongue (coating desquamates revealing beefy-red tongue with prominent papillae).

"Circumoral Pallor": Flushed, scarlet cheeks with characteristic pallor of the perioral area—a highly specific sign that helps differentiate scarlet fever from viral exanthems.

"The 10-Day Rule": Always complete 10 days of penicillin therapy, even if symptoms resolve earlier. This duration is critical for preventing Acute Rheumatic Fever, not just symptom resolution.

"Pastia's Lines": Linear petechial/purpuric streaks in flexural creases (antecubital fossae, axillae, inguinal regions). These represent capillary fragility and often persist after the generalised rash fades—a useful late diagnostic clue.

"Post-Infection Desquamation": Fine, flaky desquamation starting around day 5-7, most prominent on fingertips, palms, and soles. Can persist for 2-3 weeks. This is normal healing, not worsening disease.

---

2. Epidemiology

Demographics and Incidence

UK Resurgence (2014-Present)

The United Kingdom has experienced an unprecedented increase in scarlet fever and invasive GAS infections since 2014, reversing decades of low incidence. [5,6]

Exam Detail: Epidemiological Timeline:

• Pre-2014: Stable low incidence (~5,000 cases/year in England)
• 2014-2018: Sustained increase with peaks of 30,000+ cases annually
• 2020-2021: Temporary reduction during COVID-19 pandemic (social distancing, school closures)
• 2022-2023: Dramatic rebound with record cases and increased iGAS disease, including paediatric deaths

Proposed Mechanisms for Resurgence:

1. Molecular Changes: Emergence of emm1 and emm12 hypervirulent clones, particularly the M1UK strain with enhanced toxin production
2. "Immunity Debt": Reduced natural immunity exposure during pandemic leading to increased susceptibility
3. Co-infections: Potential viral-bacterial interactions (influenza, respiratory syncytial virus) enhancing GAS virulence
4. Environmental Factors: Unclear—no definitive link to climate, vaccination, or antibiotic prescribing patterns

Clinical Implications:

• Heightened clinical vigilance for iGAS complications
• Lower threshold for hospital assessment if red flag features present
• Enhanced public health surveillance and outbreak management

Transmission Dynamics

---

3. Aetiology and Pathophysiology

Microbiology

Organism: Streptococcus pyogenes (Lancefield Group A Streptococcus—GAS) [1,2]

Molecular Pathogenesis

Exam Detail: Streptococcal Pyrogenic Exotoxins (SPEs)—Superantigen Mechanism:

The hallmark of scarlet fever is the production of erythrogenic exotoxins, now termed Streptococcal Pyrogenic Exotoxins (SPEs). These act as superantigens with unique immunological properties. [15]

Superantigen Activity:

1. Non-Specific T-Cell Activation: SPEs bypass normal antigen processing by binding directly to MHC class II molecules outside the peptide-binding groove AND to T-cell receptors (TCR) Vβ regions
2. Massive Cytokine Release: Triggers polyclonal T-cell activation (up to 20% of T-cell population) → massive IL-1, IL-2, TNF-α, IFN-γ release
3. Vascular Effects: Cytokine storm causes:
   • Increased vascular permeability → oedema, hypotension (in severe cases)
   • Capillary dilation → erythematous rash
   • Endothelial damage → petechiae, Pastia's lines
4. Tissue Effects: Toxin-mediated desquamation of skin and mucosa

Recent Discovery (2022)—Pyroptosis Mechanism:

Groundbreaking research by Deng et al. demonstrated that SPE B (a cysteine protease) directly cleaves Gasdermin A (GSDMA), triggering pyroptosis (inflammatory programmed cell death). This mechanism explains the tissue destruction and inflammatory features of severe GAS infections. [16]

Genetic Basis:

• SPE genes located on lysogenic bacteriophages integrated into streptococcal chromosome
• Horizontal gene transfer allows acquisition of toxin genes by non-toxigenic strains
• Explains strain variability in toxin production

Pathophysiological Sequence

1. COLONISATION
   GAS adherence to pharyngeal epithelium via M protein, lipoteichoic acid
   ↓
2. LOCAL INVASION
   Bacterial replication in tonsillar crypts
   Release of extracellular enzymes (streptokinase, hyaluronidase)
   ↓
3. TOXIN PRODUCTION
   SPE-producing strains release erythrogenic exotoxins
   ↓
4. IMMUNE RESPONSE (IN NON-IMMUNE INDIVIDUALS)
   Superantigen-mediated T-cell activation
   Massive cytokine release (IL-1, IL-2, TNF-α)
   ↓
5. CLINICAL MANIFESTATIONS
   - Fever (cytokine-mediated)
   - Pharyngitis (local inflammation)
   - Rash (vascular dilation, increased permeability)
   - Strawberry tongue (gustatory papillae prominence, vascular congestion)
   - Desquamation (epithelial toxicity)
   ↓
6. RESOLUTION (WITH TREATMENT)
   Antibiotic eradication of organism
   Antibody development to specific SPE
   ↓
7. POTENTIAL COMPLICATIONS (IF UNTREATED)
   - Direct invasion: Peritonsillar abscess, iGAS
   - Immune-mediated: Rheumatic Fever (molecular mimicry), PSGN (immune complex deposition)

Why Only Some Develop the Rash?

Clinical Implication: A child can have streptococcal pharyngitis multiple times but typically develops the scarlet fever rash only once (per SPE type). [3,4]

---

4. Clinical Presentation

Symptom Timeline

Physical Examination Findings

Oropharyngeal Signs

Dermatological Signs—The Classic Rash

Facial Features

Desquamation (Convalescent Phase)

---

5. Differential Diagnosis

Scarlet fever must be differentiated from other paediatric exanthematous illnesses and streptococcal-related conditions.

Comprehensive Differential

Clinical Clues to Distinguish Scarlet Fever

1. Sandpaper-textured rash + Pastia's lines → Almost pathognomonic
2. Strawberry tongue + Exudative pharyngitis → Strongly suggests GAS
3. Circumoral pallor → Highly specific
4. Age 4-8 years + Winter/Spring + School outbreak → Epidemiological support
5. Desquamation following rash → Confirms diagnosis retrospectively

---

6. Investigations

Scarlet fever is primarily a clinical diagnosis based on characteristic features. Investigations support diagnosis, exclude differentials, and monitor for complications.

Diagnostic Investigations

Blood Investigations (If Systemically Unwell or Complications Suspected)

Investigations for Complications

Microbiological Confirmation

Exam Detail: Why Culture Throat Swabs?

1. Confirm GAS (vs viral pharyngitis)
2. Antimicrobial Stewardship: Justify antibiotic use
3. Public Health Surveillance: Track circulating strains (emm typing)
4. Outbreak Management: Identify identical strains in clusters
5. Medico-Legal Documentation: Notifiable disease

Technique for Throat Swab:

• Depress tongue with spatula
• Swab posterior pharynx and both tonsils vigorously
• Avoid tongue, buccal mucosa (oral commensals)
• Transport in appropriate medium (e.g., Amies)

Culture Interpretation:

• β-haemolytic colonies on blood agar → Presumptive GAS
• Confirmatory tests: Lancefield grouping (Group A), PYR test, Bacitracin sensitivity
• Emm typing: Molecular serotyping for epidemiology (identifies M protein type)

---

7. Management

Management Algorithm

SUSPECTED SCARLET FEVER
(Fever + Sore throat + Sandpaper rash + Strawberry tongue)
         ↓
CLINICAL ASSESSMENT
- Confirm characteristic rash (sandpaper texture, Pastia's lines)
- Examine oropharynx (exudative tonsillitis, palatal petechiae)
- Palpate cervical lymph nodes (tender anterior chain)
- Assess hydration status, systemicunwell features
- **RED FLAG SCREEN** (see below)
         ↓
RED FLAGS PRESENT?
(Sepsis, Shock, Necrotising Fasciitis, Respiratory Distress, Severe Dehydration)
    ┌──────────────────┴──────────────────┐
   YES                                    NO
    ↓                                      ↓
**HOSPITAL ADMISSION**              OUTPATIENT MANAGEMENT
- IV Access, Fluids                      ↓
- Blood Cultures, FBC, CRP, Lactate      
- **IV Benzylpenicillin** or         THROAT SWAB
  **IV Clindamycin** (if TSS)        (Culture or RADT)
- Senior Review (Paediatrics/ID)         ↓
- Consider ICU if shock/multi-organ    
                                     ANTIBIOTIC THERAPY
                                     (Initiate empirically while awaiting results)
                                         ↓
    ┌────────────────────────────────────────────────────────────────┐
    │ FIRST-LINE: **Phenoxymethylpenicillin (Penicillin V)**         │
    │ • Child 1-5 years: 125 mg QDS for 10 days                      │
    │ • Child 6-11 years: 250 mg QDS for 10 days                     │
    │ • Child ≥12 years/Adult: 500 mg QDS for 10 days                │
    │                                                                 │
    │ PENICILLIN ALLERGY (Non-anaphylaxis):                          │
    │ • Azithromycin 12 mg/kg OD for 5 days (max 500 mg/day)        │
    │ • OR Clarithromycin 7.5 mg/kg BD for 10 days (max 500 mg BD)  │
    │                                                                 │
    │ PENICILLIN ANAPHYLAXIS:                                        │
    │ • Azithromycin (as above)                                      │
    └────────────────────────────────────────────────────────────────┘
         ↓
SUPPORTIVE CARE
- Paracetamol 15 mg/kg QDS (max 1 g) OR Ibuprofen 10 mg/kg TDS
- Encourage oral fluids (prevent dehydration)
- Soft diet if dysphagia
- Rest
         ↓
INFECTION CONTROL
- **Exclude from school/nursery for 24 hours after starting antibiotics** [7]
- Hand hygiene, respiratory etiquette
- **NOTIFY Public Health** (Notifiable Disease—UKHSA in England/Wales) [5,7]
         ↓
SAFETY NETTING
- Return if: Worsening symptoms, respiratory distress, unable to drink,
  severe headache, rash becomes purpuric/non-blanching, skin becomes
  very painful (necrotising fasciitis)
- Desquamation in 1-2 weeks is normal

Red Flags Requiring Hospital Assessment

Pharmacotherapy

First-Line: Phenoxymethylpenicillin (Penicillin V)

Mechanism: β-lactam antibiotic—inhibits bacterial cell wall synthesis by binding penicillin-binding proteins.

Rationale: GAS highly susceptible; narrow spectrum; excellent oral bioavailability; minimal resistance. [7,8]

Why 10 Days?

• Eradicates GAS carriage from pharynx
• Prevents Acute Rheumatic Fever (requires complete eradication) [9]
• Reduces transmission
• Shorter courses (5-7 days) have higher relapse rates

Alternative (If QDS Compliance Concern):

• Amoxicillin 50 mg/kg/day (max 1 g) in three divided doses for 10 days
• Broader spectrum (less preferred from stewardship perspective)

Penicillin Allergy Alternatives

Caution with Macrolides: Increasing macrolide resistance in GAS (particularly emm77, emm11). If resistance suspected (treatment failure), consider switch to alternative. [7]

Severe/Invasive Disease (Hospital Setting)

Supportive Care

Infection Control and Public Health

Exam Detail: Notifiable Diseases in UK—Exam Pearls:

Scarlet fever must be notified by the registered medical practitioner who makes the diagnosis to the Proper Officer (usually Consultant in Communicable Disease Control or local Health Protection Team).

Method: Online via PHE/UKHSA portal, telephone, or written notification within 3 days (urgent notifications sooner).

Purpose:

• Surveillance (track trends, outbreaks)
• Public health action (outbreak control)
• Epidemiological research

Other Notifiable Diseases (Partial List):

• Acute infectious hepatitis, Cholera, Diphtheria, Food poisoning, Measles, Meningococcal septicaemia, Mumps, Rubella, Tuberculosis, Typhoid, Whooping cough

---

8. Complications

Complications of scarlet fever are categorised as suppurative (local extension of infection) and non-suppurative (immune-mediated post-streptococcal sequelae), plus invasive disease.

Suppurative Complications (Direct Extension)

Non-Suppurative Complications (Post-Streptococcal Sequelae)

These immune-mediated complications occur after resolution of acute infection. Acute Rheumatic Fever (ARF) is the primary reason for 10-day antibiotic therapy.

Acute Rheumatic Fever (ARF)

Post-Streptococcal Glomerulonephritis (PSGN)

PANDAS (Controversial)

Invasive Group A Streptococcus (iGAS) Disease

Invasive disease represents deep tissue invasion or toxin-mediated systemic illness. Incidence increasing in UK since 2022 resurgence. [10]

Exam Detail: Why Clindamycin in Severe iGAS?

1. Toxin Suppression: Clindamycin inhibits bacterial protein synthesis → reduces SPE toxin production (penicillin does not)
2. No Inoculum Effect: Effective even with high bacterial load (penicillin less effective in stationary-phase bacteria)
3. Immunomodulation: Suppresses pro-inflammatory cytokines

Evidence: Observational studies show reduced mortality when clindamycin added to β-lactams for severe iGAS, particularly STSS and necrotising fasciitis. [10]

Combination Therapy: Benzylpenicillin (bactericidal) + Clindamycin (toxin suppression) = synergistic.

---

9. Prognosis and Outcomes

Factors Influencing Prognosis

---

10. Evidence and Guidelines

Key Guidelines

Quality of Evidence

Recent Developments (2022-2025)

1. Streptococcal Pyrogenic Exotoxin B (SPE B) and Pyroptosis: Deng et al. (2022) discovered SPE B cleaves Gasdermin A, triggering pyroptosis—novel mechanism explaining tissue destruction in severe GAS infections. [16]

2. UK Resurgence Post-COVID-19: Karapati et al. (2024) documented surge in GAS infections post-pandemic, attributed to "immunity debt" from reduced exposure during lockdowns. [6]

3. M1UK Hypervirulent Clone: Golden et al. (2024) identified M1UK strain in Canada with enhanced virulence, associated with increased iGAS. [19]

4. Enhanced Surveillance: UKHSA implemented enhanced iGAS surveillance and lowered threshold for hospital assessment following 2022 paediatric deaths.

---

11. Examination Focus

High-Yield Viva Topics

1. Describe the Rash of Scarlet Fever

Model Answer:

"The scarlet fever rash is a fine, punctate, erythematous eruption on a diffuse erythematous base. It has a characteristic sandpaper texture when palpated, which is pathognomonic. The rash begins on the neck, upper chest, and axillae, spreading centrifugally to the trunk and limbs over 24 hours. It blanches on pressure and is particularly accentuated in flexural areas—antecubital fossae, axillae, inguinal creases—where it forms Pastia's Lines, linear petechial streaks representing capillary fragility. These lines often persist after the generalised rash fades, serving as a useful late diagnostic clue. The rash typically spares the palms and soles, though the face exhibits flushing with circumoral pallor. After 5-7 days, the rash desquamates in a fine, flaky pattern, most prominently on the fingertips and soles, persisting for 2-3 weeks."

2. What is the Significance of Strawberry Tongue?

Model Answer:

"Strawberry Tongue is a pathognomonic sign of scarlet fever, reflecting lingual vascular changes induced by streptococcal pyrogenic exotoxins. It evolves in two stages:

• White Strawberry (Days 1-3): Tongue has a white coating with prominent red fungiform and filiform papillae protruding through it, resembling a white strawberry.
• Red Strawberry (Days 4-5): The white coating desquamates, revealing a bright red, denuded tongue with markedly prominent papillae, resembling a red strawberry.

While strawberry tongue is classic for scarlet fever, it also occurs in Kawasaki disease and, rarely, toxic shock syndrome. The distinction lies in associated features: scarlet fever has exudative pharyngitis and sandpaper rash, whereas Kawasaki has prolonged fever ≥5 days, conjunctivitis, extremity changes, and polymorphous (not sandpaper) rash."

3. Why Do We Treat Scarlet Fever for 10 Days?

Model Answer:

"The 10-day treatment course is not primarily for symptom resolution—clinically, children improve within 48-72 hours—but rather for three critical reasons:

1. Prevent Acute Rheumatic Fever (ARF): This is the most important reason. ARF is an immune-mediated complication occurring 2-4 weeks post-GAS pharyngitis due to molecular mimicry between streptococcal M protein and cardiac myosin. Complete eradication of GAS from the pharynx requires 10 days of penicillin. Shorter courses have higher pharyngeal carriage rates and increased ARF risk. Notably, antibiotics do not prevent post-streptococcal glomerulonephritis, which is immune-complex mediated and already initiated during acute infection.

2. Eradicate Pharyngeal Carriage: Ensures the organism is cleared, reducing both individual relapse and ongoing transmission to contacts.

3. Reduce Transmission: Children become non-infectious 24 hours after starting antibiotics, but completing the course prevents relapse and secondary cases.

Evidence from pre-antibiotic era showed ARF incidence of 1-3% after untreated streptococcal pharyngitis; with 10-day penicillin, this drops to less than 0.1%."

4. What is Circumoral Pallor and Its Significance?

Model Answer:

"Circumoral pallor is the striking pale ring around the mouth contrasting with intensely flushed, scarlet cheeks. This is a highly specific sign of scarlet fever, helping differentiate it from other paediatric exanthems. The pathophysiology involves differential vascular reactivity: erythrogenic toxins cause widespread capillary dilation and erythema, but the perioral skin has less pronounced vascular response, resulting in relative pallor. This finding, combined with sandpaper rash and strawberry tongue, forms the classic triad that makes the diagnosis unmistakable clinically."

5. Describe Pastia's Lines

Model Answer:

"Pastia's Lines are linear petechial or purpuric streaks occurring in skin folds—antecubital fossae, axillae, inguinal creases, and popliteal fossae. They represent increased vascular fragility and capillary rupture in these areas, exacerbated by mechanical friction and increased hydrostatic pressure in dependent flexural regions. Crucially, Pastia's Lines persist after the generalised scarlet fever rash has faded, sometimes remaining visible for several days. This makes them a valuable diagnostic sign in patients presenting late, when the rash is resolving but history suggests scarlet fever."

6. What Are the Complications of Scarlet Fever?

Model Answer:

"Complications are classified into suppurative (direct bacterial extension), non-suppurative (immune-mediated post-streptococcal sequelae), and invasive disease:

Suppurative:

• Peritonsillar abscess (quinsy)—unilateral tonsillar swelling, uvular deviation, trismus
• Otitis media, sinusitis, cervical lymphadenitis
• Retropharyngeal/parapharyngeal abscess (rare, airway emergency)

Non-Suppurative (occur 1-4 weeks post-infection):

• Acute Rheumatic Fever (2-4 weeks): Carditis, migratory polyarthritis, Sydenham chorea, erythema marginatum, subcutaneous nodules. Diagnosed via Jones Criteria. Prevented by 10-day penicillin.
• Post-Streptococcal Glomerulonephritis (1-3 weeks): Haematuria, oedema, hypertension, low C3. NOT prevented by antibiotics (immune complexes already formed during acute infection). Usually self-limiting in children.
• PANDAS (controversial): Sudden-onset OCD, tics post-GAS infection.

Invasive GAS Disease (iGAS):

• Bacteraemia/sepsis (10-15% mortality)
• Necrotising fasciitis (20-30% mortality)—surgical emergency
• Streptococcal Toxic Shock Syndrome (30-50% mortality)—requires clindamycin + IVIG

The distinction between ARF (preventable) and PSGN (not preventable) is high-yield for exams."

7. What is the Pathophysiology of the Scarlet Fever Rash?

Model Answer:

"The rash results from erythrogenic exotoxins—now termed Streptococcal Pyrogenic Exotoxins (SPEs)—produced by lysogenic bacteriophage-carrying GAS strains. These toxins function as superantigens, bypassing normal antigen processing by binding directly to MHC class II molecules and T-cell receptors, triggering massive polyclonal T-cell activation (up to 20% of T-cells). This causes a cytokine storm with release of IL-1, IL-2, TNF-α, and IFN-γ.

The systemic cytokine release induces:

• Fever (IL-1, TNF-α)
• Vascular dilation and increased permeability → erythematous rash, oedema
• Capillary fragility → petechiae, Pastia's Lines
• Epithelial toxicity → subsequent desquamation

Importantly, the rash develops only in non-immune individuals—those lacking antibodies to the specific SPE. After one episode, individuals develop toxin-specific immunity, so subsequent GAS pharyngitis presents without the rash (though strep throat still occurs). Recent research (Deng et al., 2022) identified that SPE B cleaves Gasdermin A, triggering pyroptosis, a novel mechanism explaining tissue destruction in severe infections."

8. Why Has Scarlet Fever Re-emerged in the UK?

Model Answer:

"The UK experienced a dramatic resurgence of scarlet fever from 2014, with cases increasing from ~5,000/year historically to >30,000 in peak years, alongside increased invasive GAS disease. After a temporary reduction during COVID-19 lockdowns (2020-2021), cases surged again in 2022-2023, including severe iGAS and paediatric deaths.

Proposed mechanisms:

1. Bacterial Evolution: Emergence of hypervirulent clones, particularly emm1 and emm12 genotypes (including the M1UK strain), with enhanced toxin production and tissue invasiveness.

2. "Immunity Debt" Hypothesis: Reduced natural GAS exposure during pandemic social distancing/lockdowns → decreased population immunity → increased susceptibility when social mixing resumed.

3. Viral-Bacterial Synergy: Possible co-infections (influenza, RSV) enhancing GAS virulence through epithelial damage or immune modulation.

4. Environmental/Unknown Factors: No definitive links to climate, antibiotic prescribing, or vaccination changes.

Clinical implications: Heightened vigilance for iGAS, lower threshold for hospital assessment with red flags, enhanced public health surveillance, and continued emphasis on 10-day antibiotic courses to prevent complications."

Common OSCE/Clinical Exam Scenarios

Scenario 1: Rash Assessment

Examiner: "This 5-year-old has a rash. Please examine."

Approach:

1. Observe rash: Fine, punctate, erythematous, widespread (trunk, limbs)
2. Palpate: Sandpaper texture
3. Inspect flexures: Look for Pastia's Lines (axillae, antecubital fossae, groin)
4. Examine face: Flushed cheeks, circumoral pallor
5. Examine mouth: Open mouth → Strawberry Tongue, pharyngeal erythema
6. Palpate neck: Tender anterior cervical lymphadenopathy
7. Blanching test: Press rash → blanches
8. Ask about fever, sore throat

Diagnosis: "This child has scarlet fever, evidenced by the sandpaper-textured rash with Pastia's Lines, strawberry tongue, circumoral pallor, and exudative pharyngitis in the context of fever."

Scenario 2: Parent Discussion (Communication Station)

Task: Explain scarlet fever diagnosis and management to parent.

Structure:

1. Explain condition: "Your child has scarlet fever, a bacterial infection caused by Streptococcus bacteria that produce toxins. This causes the sore throat, fever, and rash."
2. Natural history: "The rash is rough like sandpaper and will fade in about 5-7 days. Afterward, the skin may peel—especially on fingers and toes—for 2-3 weeks. This is normal healing."
3. Treatment: "We'll prescribe penicillin antibiotics for 10 days. It's crucial to complete the full course, even when your child feels better, to prevent complications affecting the heart and kidneys."
4. School exclusion: "Keep your child home until 24 hours after starting antibiotics, then they can return if well."
5. Red flags: "Come back if: difficulty breathing, unable to drink, severe headache, rash becomes purple/doesn't fade, or severe pain in any area."
6. Questions: Address concerns (contagiousness, scarring—reassure no permanent marks, safe for siblings if they've had it before).

---

12. Patient and Layperson Explanation

What is Scarlet Fever?

Scarlet Fever is a bacterial infection caused by a type of bacteria called Group A Streptococcus (the same germ that causes "strep throat"). Some strains of this bacteria produce toxins that cause a distinctive red rash all over the body, along with fever and a sore throat.

Who Gets Scarlet Fever?

Scarlet Fever mainly affects children between 2 and 10 years old, with peak cases in 4-8-year-olds. It's less common in younger babies (who have some protection from their mother's antibodies) and in adults (who usually have immunity from previous exposures).

It spreads easily in places where children are in close contact, like schools, nurseries, and households, especially during winter and spring.

How Does It Spread?

Scarlet fever spreads through:

• Coughing and sneezing (respiratory droplets)
• Direct contact with an infected person's saliva or nasal secretions
• Rarely, touching surfaces contaminated with the bacteria

The incubation period (time from exposure to symptoms) is 2-4 days.

What Are the Symptoms?

Scarlet fever typically starts suddenly with:

1. High fever (38.5-40°C / 101-104°F)
2. Sore throat (often with white spots on tonsils)
3. Headache, body aches, feeling unwell
4. Swollen neck glands (tender lumps on sides of neck)

Within 1-2 days, a bright red rash appears:

• Looks like: Tiny red bumps on red skin (like a sunburn with goosebumps)
• Feels like: Rough, like fine sandpaper (this is a key clue!)
• Starts on: Neck, chest, armpits
• Spreads to: Body, arms, legs (but usually spares palms and soles)
• Fades when pressed (blanches)

Other signs:

• "Strawberry Tongue": At first, white with red spots (like a white strawberry); later, bright red with bumps (like a red strawberry)
• Flushed cheeks with a pale area around the mouth
• Darker lines in skin creases (armpits, elbows, groin)—called "Pastia's Lines"

After about 5-7 days, the rash fades and skin starts to peel, especially on fingertips and toes. This can last 2-3 weeks and is a normal part of healing.

Is It Serious?

Most cases of scarlet fever are mild and easily treated with antibiotics. With proper treatment, children recover fully within a week or two.

However, without treatment, scarlet fever can lead to complications, including:

• Ear infections, sinus infections
• Abscess near the tonsils (quinsy)
• Rheumatic Fever (affects the heart—rare nowadays with antibiotics)
• Kidney problems (post-streptococcal glomerulonephritis)
• Severe invasive infections (very rare but serious)

This is why completing the full course of antibiotics is crucial, even after your child feels better.

How is Scarlet Fever Diagnosed?

Doctors usually diagnose scarlet fever by:

• Examining the rash (sandpaper texture, pattern)
• Looking at the throat (red, sometimes with white spots)
• Checking the tongue ("strawberry" appearance)
• Sometimes taking a throat swab to confirm the bacteria

How is It Treated?

Antibiotics: The main treatment is Penicillin V (phenoxymethylpenicillin) given four times a day for 10 days. If your child is allergic to penicillin, alternatives like azithromycin are used.

Why 10 days? Even though your child will feel better in 2-3 days, the full 10 days is essential to:

• Completely clear the bacteria
• Prevent complications (especially rheumatic fever, which affects the heart)
• Stop spreading the infection to others

Symptom relief:

• Paracetamol or ibuprofen for fever and pain
• Plenty of fluids (water, diluted juice, ice lollies)
• Soft, cool foods if swallowing is painful (yoghurt, soup, ice cream)
• Rest

When Can My Child Return to School?

Your child should stay home until 24 hours after starting antibiotics and is feeling well. After this, they're no longer contagious and can return to school/nursery.

Can Scarlet Fever Come Back?

Once your child has had scarlet fever and developed immunity to the specific toxin, they're unlikely to get the rash again (from that toxin type). However, they can still get strep throat (without the rash) from different strains of the bacteria.

When Should I Seek Urgent Medical Help?

Contact your doctor or go to A&E if your child has:

• Difficulty breathing or rapid breathing
• Unable to drink or severe dehydration (dry mouth, no tears, no urine)
• Very drowsy or difficult to wake
• Severe headache or stiff neck
• Rash that doesn't fade when pressed (glass test) or becomes purple
• Severe pain in a limb or body part (especially if skin looks discoloured)
• Gets worse instead of better after starting antibiotics

Is Scarlet Fever Notifiable?

Yes. In the UK, scarlet fever is a notifiable disease, meaning doctors must report cases to public health authorities. This helps track outbreaks and protect the community.

Can It Be Prevented?

There's no vaccine for scarlet fever. The best prevention is:

• Good hand hygiene (wash hands frequently with soap)
• Covering coughs and sneezes (into elbow, not hands)
• Avoiding sharing utensils, cups, towels with infected people
• Keeping unwell children home from school/nursery

Key Takeaways for Parents

✅ Scarlet fever is a bacterial infection causing fever, sore throat, and a sandpaper-like rash

✅ It's treated with antibiotics for 10 days—finish the full course!

✅ Children are no longer contagious 24 hours after starting antibiotics

✅ Skin peeling after the rash is normal and not a sign of worsening

✅ Most children recover fully with no lasting effects

✅ Watch for warning signs and seek help if your child deteriorates

---

13. References

Primary Sources

1. Sabir S, Ramphul K. Scarlet Fever. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. PMID: 29939666.

2. Newberger R, Wilkins AL, Shulman ST. Group A Streptococcal Infections. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. PMID: 32644666.

3. Wannamaker LW. Streptococcal toxins. Rev Infect Dis. 1983 Sep-Oct;5 Suppl 4:S723-32. DOI: 10.1093/clinids/5.supplement_4.s723. PMID: 6356291.

4. Zabriskie JB. The role of temperate bacteriophage in the production of erythrogenic toxin by group A streptococci. J Exp Med. 1964 May 1;119:761-80. DOI: 10.1084/jem.119.5.761. PMID: 14157029.

5. UK Health Security Agency. Scarlet fever: symptoms, diagnosis and treatment. GOV.UK. Updated 2022. Accessed January 2026.

6. Karapati E, Dasoula F, Tsiatsiou O, et al. Group A Streptococcus Infections in Children: Epidemiological Insights Before and After the COVID-19 Pandemic. Pathogens. 2024 Nov 15;13(11):1007. DOI: 10.3390/pathogens13111007. PMID: 39599560.

7. Managing scarlet fever. Drug Ther Bull. 2017 Sep;55(9):106-109. DOI: 10.1136/dtb.2017.8.0529. PMID: 28882851.

8. Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012 Nov 15;55(10):e86-102. DOI: 10.1093/cid/cis629. PMID: 22965026.

9. Hahn RG, Knox LM, Forman TA. Evaluation of poststreptococcal illness. Am Fam Physician. 2005 May 15;71(10):1949-54. PMID: 15926411.

10. Spencer RC. Invasive streptococci. Eur J Clin Microbiol Infect Dis. 1995;14 Suppl 1:S26-32. DOI: 10.1007/BF02112622. PMID: 7729468.

11. Leung TN, Hon KL, Leung AKC. Group A Streptococcus disease in Hong Kong children: an overview. Hong Kong Med J. 2018 Dec;24(6):593-601. DOI: 10.12809/hkmj187275. PMID: 30416105.

12. Matsubara VH, Neves Silva ME, Ishikawa KH, et al. Recrudescence of Scarlet Fever and Its Implications for Dental Professionals. Int Dent J. 2023 Jun;73(3):289-296. DOI: 10.1016/j.identj.2023.03.009. PMID: 37062653.

13. Tewfik TL, Al Garni M. Tonsillopharyngitis: clinical highlights. J Otolaryngol. 2005 Jun;34 Suppl 1:S45-9. DOI: 10.2310/7070.2005.34s106. PMID: 16089240.

14. Smith KL, Patel S. Tonsillitis and Tonsilloliths: Diagnosis and Management. Am Fam Physician. 2023 Jan;107(1):49-57. PMID: 36689967.

15. Yamamoto M, Nair GB, Albert MJ, et al. High level expression of Streptococcus pyogenes erythrogenic toxin A (SPE A) in Escherichia coli and its rapid purification by HPLC. FEMS Microbiol Lett. 1995 Oct 15;132(3):249-53. DOI: 10.1111/j.1574-6968.1995.tb07840.x. PMID: 7590174.

16. Deng W, Bai Y, Deng F, et al. Streptococcal pyrogenic exotoxin B cleaves GSDMA and triggers pyroptosis. Nature. 2022 Feb;602(7897):496-502. DOI: 10.1038/s41586-021-04384-4. PMID: 35110732.

17. Drug and Therapeutics Bulletin. Managing scarlet fever. BMJ. 2018 Aug 30;362:k3005. DOI: 10.1136/bmj.k3005. PMID: 30166279.

18. NICE. Sore throat (acute): antimicrobial prescribing. NICE guideline [NG84]. Published 2018. Updated 2024.

19. Golden AR, Baxter M, Suley C, et al. Invasive Group A Streptococcus Hypervirulent M1(UK) Clone, Canada, 2018-2023. Emerg Infect Dis. 2024 Nov;30(11):2367-2371. DOI: 10.3201/eid3011.241068. PMID: 39428565.

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference only. Clinical decisions should always account for individual patient circumstances, local guidelines, and specialist input. This resource does not replace clinical judgment or consultation with appropriate specialists.